BioMarin Drops Pompe Drug In Hunt For Profitability

10 Jun 2016

• By Lisa LaMotta

BioMarin continues to pare down its portfolio in order to focus its cash on higher value assets in an effort to reach profitability.

Less than two weeks after BioMarin Pharmaceutical Inc. opted to discontinue the entire development of the Prosensa portfolio, the company mentioned it would be abandoning another mid-stage asset for Pompe disease as it tries to be more prudent about spending.

BioMarin has said publicly that it hopes to break even or better in 2017, but that goal is going to...